ZNTL4:05 PMZentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updateszentalis.com
ZNTL5:00 PMZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)zentalis.com
ZNTL4:15 PMZentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026zentalis.com
ZNTL5:00 PMZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)zentalis.com
ZNTL4:05 PMZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategyzentalis.com
ZNTL5:39 PMZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026Presentation / Abstract • Phase 1zentalis.com